Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Spyre Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 45
- −5 vs. Q4 2022
- Shares held
- 41.3M
- −1.10M (−2.6%) vs. Q4 2022
- Total value
- $12.0M
- −$7.10M (−37.2%) vs. Q4 2022
- New holders
- 3
- 9 more added
- Sold out
- 8
- 9 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SYRE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 265 | $8.52B |
| Q1 2026 | 198 | $4.16B |
| Q4 2025 | 153 | $2.65B |
| Q3 2025 | 137 | $1.08B |
| Q2 2025 | 129 | $952.6M |
| Q1 2025 | 129 | $1.00B |
| Q4 2024 | 131 | $1.39B |
| Q3 2024 | 119 | $1.51B |
| Q2 2024 | 107 | $1.18B |
| Q1 2024 | 103 | $1.21B |
| Q4 2023 | 54 | $601.0M |
| Q3 2023 | 29 | $43.9M |
| Q2 2023 | 44 | $31.9M |
| Q1 2023 | 45 | $12.0M |
| Q4 2022 | 51 | $19.2M |
| Q3 2022 | 55 | $23.5M |
| Q2 2022 | 67 | $24.8M |
| Q1 2022 | 84 | $95.4M |
| Q4 2021 | 86 | $189.4M |
| Q3 2021 | 77 | $322.5M |
| Q2 2021 | 78 | $285.8M |
| Q1 2021 | 84 | $328.7M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Spyre Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 5,347,689 | $1.55M | 0.19% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 4,558,012 | $1.32M | 0.13% | −53,290−1.2% | Reduced |
| Suvretta Capital Management, LLC | 4,059,894 | $1.18M | 0.06% | 00.0% | Unchanged |
| Millennium Management LLC | 3,736,483 | $1.08M | 0.00% | +605,004+19.3% | Added |
| Rock Springs Capital Management LP | 3,413,906 | $990.0K | 0.02% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 3,410,106 | $988.9K | 0.01% | 00.0% | Unchanged |
| Sio Capital Management, LLC | 3,004,959 | $871.4K | 0.43% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,997,597 | $579.3K | 0.00% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,797,221 | $521.2K | 0.01% | 00.0% | Unchanged |
| Aisling Capital Management LP | 1,691,151 | $490.4K | 0.24% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,500,000 | $435.0K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 1,391,381 | $402.0K | 0.00% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 883,720 | $256.3K | 0.05% | 00.0% | Unchanged |
| BlackRock Inc. | 648,648 | $188.1K | 0.00% | +2,694+0.4% | Added |
| Sphera Funds Management Ltd. | 646,478 | $187.5K | 0.04% | +205,641+46.6% | Added |
| Geode Capital Management, LLC | 600,455 | $174.1K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 320,498 | $92.9K | 0.00% | −73,140−18.6% | Reduced |
| Assenagon Asset Management S.A. | 318,451 | $92.4K | 0.00% | 00.0% | Unchanged |
| University of Texas/Texas Am Investment Managment Co | 245,678 | $71.0K | 0.03% | 00.0% | Unchanged |
| Carlyle Group Inc. | 240,500 | $69.0K | 0.00% | +240,500 | New |
| State Street Corp | 214,989 | $62.3K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 210,800 | $61.1K | 0.00% | −62,000−22.7% | Reduced |
| Renaissance Technologies LLC | 181,100 | $53.0K | 0.00% | +30,000+19.9% | Added |
| Bridgeway Capital Management, LLC | 150,000 | $43.5K | 0.00% | 00.0% | Unchanged |
| ExodusPoint Capital Management, LP | 117,479 | $34.0K | 0.00% | +12,217+11.6% | Added |
| Fan Yu | 112,044 | $32.5K | 1.79% | 00.0% | Unchanged |
| Franklin Street Advisors Inc | 105,800 | $31.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 97,927 | $28.4K | 0.00% | +11,502+13.3% | Added |
| Blair William & Co | 60,302 | $17.5K | 0.00% | −16,292−21.3% | Reduced |
| Jane Street Group, LLC | 42,763 | $12.4K | 0.00% | +42,763 | New |
| Ritholtz Wealth Management | 41,774 | $12.1K | 0.00% | −34,716−45.4% | Reduced |
| Tower Research Capital LLC (TRC) | 37,381 | $11.0K | 0.00% | +19,537+109.5% | Added |
| Bank of America Corp | 35,230 | $10.2K | 0.00% | +19,460+123.4% | Added |
| Franklin Resources Inc | 31,364 | $9.10K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 23,233 | $6.74K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 19,295 | $6.00K | 0.00% | +19,295 | New |
| Morgan Stanley | 13,656 | $3.96K | 0.00% | −66,805−83.0% | Reduced |
| Wells Fargo & Company | 8,224 | $2.38K | 0.00% | +5,681+223.4% | Added |
| Group One Trading, L.P. | 2,882 | $836 | 0.00% | −300−9.4% | Reduced |
| BNP Paribas Arbitrage, SA | 396 | $115 | 0.00% | −2,572−86.7% | Reduced |
| Barclays PLC | 99 | $29 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 7 | $2 | 0.00% | −1−12.5% | Reduced |
| JPMorgan Chase & Co | 1,068 | $0 | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 56 | $0 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 2,860 | – | – | 00.0% | Unchanged |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −1,048,697−100.0% | Sold out |
| Ghost Tree Capital, LLC | 0 | $0 | 0.00% | −800,000−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −50,943−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −49,978−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −17,200−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −15,472−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −14,722−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,272−100.0% | Sold out |
| Abingworth LLP | – | – | – | – | Not filed |